Net income for Q2 rose sharply yr/yr, driven by patient affordability and plasma business growth
Company raised full-year 2026 outlook for revenue and adjusted EBITDA
Outlook and result drivers
Paysign raises 2026 revenue outlook to $114 mln–$117 mln from prior guidance
Company sees Q3 2026 revenue of $28.5 mln–$30 mln
Paysign expects to exit Q3 2026 with 165–170 active patient affordability programs and 561–563 plasma centers
Pharma program expansion - Co said pharma revenue rose 89% on addition of 51 net patient affordability programs and higher claims processing
Plasma utilization - Plasma revenue rose 21% as existing centers saw higher average revenue and more loads per center, offsetting a decline in total centers
Margin expansion - Gross and operating margins improved due to a greater mix of pharma revenue and expense discipline
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the business support services peer group is "buy"
Wall Street's median 12-month price target for Paysign Inc is $11.00, about 18.5% above its August 4 closing price of $9.28
The stock recently traded at 33 times the next 12-month earnings vs. a P/E of 24 three months ago
PAYS•
